Factors Affecting First-Line Triple Therapy of Helicobacter pylori Including CYP2C19 Genotype and Antibiotic Resistance

被引：0
作者：
Ju Yup Lee
Nayoung Kim
Min Soo Kim
Yoon Jin Choi
Jung Won Lee
Hyuk Yoon
Cheol Min Shin
Young Soo Park
Dong Ho Lee
Hyun Chae Jung
机构：
[1] Seoul National University Bundang Hospital,Department of Internal Medicine
[2] Seoul National University College of Medicine,Department of Internal Medicine and Liver Research Institute
来源：
Digestive Diseases and Sciences | 2014年 / 59卷
关键词：
Clarithromycin; Treatment failure; Drug resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1235 / 1243
页数：8
相关论文
共 50 条
  • [21] Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis
    Murata, Masaki
    Sugimoto, Mitsushige
    Mizuno, Hitomi
    Kanno, Takeshi
    Satoh, Kiichi
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (02)
  • [22] Clopidogrel resistance in extremely high cardiovascular risk patients with genotype CYP2C19
    Cardenas, Liliana
    Aymen Abdullah, Ali
    Jaramillo, Gabriela
    Cardenas, Paul
    Galvez, Gabriela
    Hidalgo, Fernando
    REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2023, 52 (03): : 134 - 137
  • [23] Comparison of the traditional triple and a new bismuth-containing quadruple therapy in the first-line eradication of Helicobacter pylori
    Varga Mate
    Dracz Lajos
    Kolbenheyer Erik
    Varga Ferenc
    Patai Arpad, V
    Solymosi Norbert
    Patai Arpad
    ORVOSI HETILAP, 2019, 160 (34) : 1340 - 1345
  • [24] Hp-normogram (normo-graham) for Assessing the Outcome of H-pylori Therapy: Effect of Resistance, Duration, and CYP2C19 Genotype
    Graham, David Y.
    HELICOBACTER, 2016, 21 (02) : 85 - 90
  • [25] Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori
    Castro-Fernandez, M.
    Lamas, E.
    Perez-Pastor, A.
    Pabon, M.
    Aparcero, R.
    Vargas-Romero, J.
    Larraona, J. L.
    Romero-Gomez, M.
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2009, 101 (06) : 395 - 398
  • [26] Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori
    Wu, Meng-Chieh
    Wang, Yao-Kuang
    Liu, Chung-Jung
    Yu, Fang-Jung
    Kuo, Fu-Chen
    Liu, Min-Li
    Kuo, Chao-Hung
    Wu, Deng-Chyang
    Huang, Yao-Kang
    Wu, I-Chen
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2017, 2017
  • [27] Bismuth containing quadruple therapy versus tailored therapy as first-line treatments for Helicobacter pylori infection in a high clarithromycin resistance area
    Cha, Boram
    Bang, Byoung Wook
    Shin, Jong Beom
    Ko, Eun Jung
    Ko, Weonjin
    Kwon, Kye Sook
    Shin, Yong Woon
    Suh, Young Ju
    Kim, Hyungkil
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2021, 56 (09) : 1017 - 1022
  • [28] Ten-day triple therapy versus sequential therapy versus concomitant therapy as first-line treatment for Helicobacter pylori infection
    Ang, Tiing Leong
    Fock, Kwong Ming
    Song, Mingjun
    Ang, Daphne
    Kwek, Andrew Boon Eu
    Ong, Jeannie
    Tan, Jessica
    Teo, Eng Kiong
    Dhamodaran, Subbiah
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 (07) : 1134 - 1139
  • [29] The Efficacy of Bismuth Quadruple Therapy, Sequential Therapy, and Hybrid Therapy as a First-Line Regimen for Helicobacter pylori Infection Compared with Standard Triple Therapy
    Koroglu, M.
    Ayvaz, M. A.
    Ozturk, M. A.
    NIGERIAN JOURNAL OF CLINICAL PRACTICE, 2022, 25 (09) : 1535 - 1541
  • [30] Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori
    Adachi, Teppei
    Matsui, Shigenaga
    Watanabe, Tomohiro
    Okamoto, Kazuki
    Okamoto, Ayana
    Kono, Masashi
    Yamada, Mitsunari
    Nagai, Tomoyuki
    Komeda, Yoriaki
    Minaga, Kosuke
    Kamata, Ken
    Yamao, Kentaro
    Takenaka, Mamoru
    Asakuma, Yutaka
    Sakurai, Toshiharu
    Nishida, Naoshi
    Kashida, Hiroshi
    Kudo, Masatoshi
    ONCOLOGY, 2017, 93 : 15 - 19
12345